More about

National Institutes Of Health

News
October 10, 2019
1 min read
Save

NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.

News
October 10, 2019
1 min read
Save

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Phase 1 study to determine the safety and feasibility of using HERV-E TCR-transduced autologous T Cells in patients with metastatic clear-cell renal-cell carcinoma.

News
October 10, 2019
1 min read
Save

HA-1 T TCR T Cell Immunotherapy for the Treating of Patients with Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Phase 1 study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor for children and adults with recurrent acute leukemia after allogeneic hematopoietic stem cell transplantation.

News
October 10, 2019
1 min read
Save

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.

News
October 05, 2019
1 min read
Save

The Wistar Institute researcher receives NIH New Innovator Award

The Wistar Institute researcher receives NIH New Innovator Award

The NIH presented its New Innovator Award to Zachary T. Schug, PhD, assistant professor in the molecular and cellular oncogenesis program at The Wistar Institute in Philadelphia.

News
October 02, 2019
1 min read
Save

Second Sight given $2.4 million NIH grant

The National Institutes of Health have awarded a $2.4 million 4-year grant to Second Sight Medical Products for the development of spatial localization and mapping technology, according to a press release.

News
September 18, 2019
6 min read
Save

AACR Cancer Progress Report: Past federal investments in NIH spurring breakthroughs in care

AACR Cancer Progress Report: Past federal investments in NIH spurring breakthroughs in care

The American Association for Cancer Research today released its annual Cancer Progress Report, which reflects how prior investment in the NIH is paying dividends in terms of advances across the spectrum of cancer care.

News
August 19, 2019
16 min read
Save

Lumpers, Splitters, and the Move Toward New Taxonomy for Rheumatology

Lumpers, Splitters, and the Move Toward New Taxonomy for Rheumatology

Historians attribute Philip II of Macedon — father of Alexander the Great — as the source of the motto and political principle known as “divide and conquer.” As a ruling technique, the maxim worked, with Phillip ultimately ruling over most of classical Greece; a success that would be repeated with Julius Caesar and Napoleon Bonaparte in the centuries to follow.

News
August 14, 2019
3 min read
Save

New findings provide additional evidence of AFM, enterovirus link

Testing of 14 patients with acute flaccid myelitis, or AFM, showed they had antibodies against enteroviruses, especially EV-D68, in their cerebrospinal fluid at a significantly higher rate than controls, supporting “the plausibility of a link” between enterovirus infection and AFM, researchers reported in mBio.

News
August 03, 2019
1 min read
Save

NCI awards $11 million grant to NYU Langone to develop immunotherapy biomarkers

NCI awards $11 million grant to NYU Langone to develop immunotherapy biomarkers

NCI awarded a 5-year, $11 million grant to NYU Langone Health’s Ronald O. Perelman department of dermatology to develop biomarkers that can predict whether immunotherapy will be effective for specific patients.

View more